The objective of this article is to study the survival pattern and the prognostic factors for HIV-infected children on antiretroviral therapy (ART) for two and half years at the Government Hospital of Thoracic Medicine, Tambaram, Chennai, India. We studied 295 children who were initiated on ART from 1 April 2004 to 30 September 2006 at a large, public tertiary care facility in Chennai, India. Weight for age Z-score was calculated. Survival curves and Cox proportional hazard models were used to identify risk factors for mortality. The mean and median follow up was 11 and 10 months, respectively. The cumulative survival probability at 6, 12, 18, 24 and 30 months was 93, 90, 89.7, 89.7 and 89.7%, respectively. Of the children who died, about 50% died within the first month. Nearly 6% of the children had adherence less than 95%. The children who had a baseline CD4 percent less than or equal to 14% had significantly (p < 0.05) higher mortality as compared to children who had 20% or more. The children who had negative or no change in weight for age Z-score and hemoglobin had 18.9 (3.7-95.7) times significantly higher mortality as compared to children who had positive change in both variables (p < 0.001). The sensitivity, specificity and likelihood ratio of the positive test for negative change or no change in HB was 65%, 85% and 4.3, respectively. Similarly, these were 80%, 73% and 3% for negative or no change in Absolute Lymphocyte Count (ALC). These findings indicate the feasibility and effectiveness of implementing an ART program in a large government hospital in India. Simple nutritional variable hemoglobin and immunologic variable ALC could be used to monitor the progression of disease in children.
Introduction
The world's second-most populous country, India, is experiencing a highly varied HIV epidemic, which appears to be stable or diminishing in some parts while growing at a modest rate in others. Approximately, 5.7 million (3.4-9.4 million) people, of which 5.2 million were adults aged 15-49 years, were living with HIV in 2005 [1] . While the national HIV prevalence based on the Ante Natal Clinic (ANC) surveillance data is estimated to be 0.9%, there are many areas in the country that are seeing significantly higher prevalence. The prevalence of HIV among mothers who attended Prevention of Parent to Child Transmission (PPTCT) programs in 30-district headquarters' hospital in Tamilnadu state was 0.69 and 0.41 in 2002 and 2005, respectively [2] . The Government of India has initiated the Antiretroviral Therapy (ART) program in April 2004. HIV-positive children were also provided with ART since then. Though the free ART program was initiated in 2004, only 4% of the estimated 777 000 HIV-infected persons in need of ART are receiving such therapy through the government system [3] . The government ART program has covered nearly 42 000 patients with free ART through 96 centers in 29 states of India in the last two and half years and is expected to cover 10 000 children by March 2007. India's National HIV/AIDS Control Organization (NACO) has recently developed its 2006-11 HIV/ AIDS Strategic Plan (NACP III) that includes support to place 40 000 children on ART at 250 government ART centers by 2010. However, there is little data on the effectiveness of this program after 2.5 years on survival and compliance in India.
Clinical trials conducted among limited numbers of perinatally HIV-infected children have shown that combined ART reduces viral load and increases CD4 lymphocyte counts [4] [5] [6] [7] . However, few studies have evaluated the effectiveness of combination therapy on survival among children in settings other than clinical trials [8, 9] . Reddi et al. [8] , based on the cohort of 151 children, have shown that chronic gastroenteritis and no HIV positive primary care giver were significantly associated with mortality, though there was only 13 deaths. McConnel et al. [10] have shown that the cohort of children who received triple ART had significantly longer survival as compared to others. Gortmaker et al. [11] have shown that the use of combination therapy including protease inhibitors has markedly reduced mortality [hazard ratio (HR) ¼ 0.33, 95% CI: 0.19-0.58]). Also de Martino et al. (2000) have shown that the risk of death in children receiving triple drug therapy was significantly lower as compared to no ART (HR ¼ 0.29, 95% CI: 0.13-0.67). They have also shown that the mortality was lower for younger children, male sex, higher baseline CD4% lymphocytes, race and higher education of parents. However, there is little information on these factors in Asia, especially on the government-sponsored ART program and the risk factors for survival in children. In India, the challenges involved in providing ART include high rates of poverty, malnutrition, limited access to care, stigma and tuberculosis. Therefore, the objective of this article is to present the survival pattern and the prognostic factors for HIV-infected children having been treated on ARVs for as long as two and half a years, at the Government Hospital of Thoracic Medicine (GHTM), Tambaram, Chennai, India.
Methods

GHTM at
Tambaram, Chennai is a tertiary care referral hospital that has historically provided care to tuberculosis patients. Over the past 2 decades, the GHTM has become the largest public HIV care center in the country. From 2001 to 2005, over 60 000 HIV-infected patients were seen at the hospital. In April 2004, NACO began sponsoring free ART program at GHTM, which provides free HIV care (including ART) to eligible patients accessing care at government facilities.
As of September 2006 at GHTM, Tambaram, 154 913 patients have been counseled and tested for HIV. 61 531 (39.7%) were found to be infected with HIV. Of those found to be infected with HIV, 4096, including 295 children, have been receiving ART. 497 children were screened for ART program based on the symptoms and signs indicating WHO clinical stage III and/or IV at the time of visit to ART out-patient department. The children who had either CD4% <20 or WHO clinical stage III and/or IV were recruited for ART. GHTM has also received significant support from the US Centers for Disease Control and the Tamil Nadu State AIDS Control Society to support this program in the form of laboratory, personnel and patient-level record keeping enhancements. One area of support was the implementation of an electronic medical record system, was launched in December 2001. This system has allowed for patient-level longitudinal follow up for all patients accessing care at GHTM. Patients are provided unique patient numbers and are tracked during the follow-up visits. Data collected at the out-patient counters, inpatient services, laboratory, voluntary HIV counseling and testing (VCTC) and ART facilities at the hospital are linked for more efficient care and analyses.
Approval for this analysis was given by GHTM's Institutional Review Board, a multidisciplinary body that has been formed to review all study protocols for ethical considerations for research involving patients at that facility.
Treatment HIV-infected children, found to be eligible by NACO Guidelines (2004) are enrolled in ART Program where they receive their free treatment and clinical check-up during monthly visits to GHTM, as per NACO and WHO guidelines [12] . An ART regimen consists of Stavudine (d4T) or Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) or Efavirenz (EFV). The exact ART regimen was determined by a whether or not the patient was anemic (d4T substituted for AZT) or if they were receiving a rifampicin-based treatment for tuberculosis (EFV substituted for NVP).
In addition to a monthly clinical assessment, ART children's parents or guardians are provided with multiple counseling sessions, which look to address psychological readiness for treatment, treatment adherence and follow-up support. Children's parents or guardians are also asked to identify a treatment supporter, such as a family member, friend or organization, which will assist them during treatment in these areas.
Clinical measurements
Body weight was measured at every monthly visit. Laboratory monitoring including the baseline CD4 percent by Flow cytometry was done every 6 months. Patient's Hemoglobin level (HB) and Absolute Lymphocyte Count (ALC), as the part of complete hemogram. Renal and liver function tests were performed every month during the first year and every 3 months thereafter.
Statistical methods
Patient data was obtained from GHTM's electronic medical record system. Data on parents, when available, were linked with the records for the children using anonymous patient identification number. Kaplan-Meier cumulative probability survival estimates were used. For patients who did not reach the end point, the data were censored at the date of the last visit. Tarone-Ware statistics were used to compare the survival curves. However, the survival plots were based on cumulative survival probability estimated using Life table method with 1 month time interval. Weight for age Z-score was calculated using Nutrition program in EPIINFO software version 3.2 nutrition program. Study variables (socio-demographic, HIV staging at baseline, opportunistic infections at baseline and during follow up, immunological variables CD4 percent T-cell, ALC and nutritional variables, HB, bodyweight and drug adherence, which were significant at 20% level in Tarone-Ware statistics) were selected as potential variables for multivariate Cox proportional hazards (PHs) model. Absolute change in CD4 was not included in the second model as CD4 T-cell percent was measured once in 6 months and therefore, small number of patients with multiple CD4 percent T-cell values. Model assumptions were evaluated using log log(s(t)) plot. In reporting descriptive statistics, means of continuous variables are given with standard deviations (SD) in parenthesis while medians are given with inter quartile ranges (IQR) in parenthesis.
Results
Enrollment
Since April 2004, there were 819 new HIV-infected children (i.e. those less than 15 years of age) receiving care at GHTM. Of these, 497 HIV patients were screened for and 295 initiated on ART. Of the 295 children, 166 (56.3%) and 129 (43.7%) were male and female patients, respectively. As of September 2006, 260 (88%) of these children were still alive and being treated, 24 (8%) were known to have died. The remaining children were lost to follow up or stopped taking treatment. The socio-demographic distribution of new HIV-positive children, HIVpositive children who were screened for ART program and the children who received ART at GHTM is presented in Table 1 .
The ART program enrolls only patients from the state of Tamil Nadu. Therefore the socio-demographic characteristics of the children who received ART at the GHTM were compared to the children who were screened for ART and newly diagnosed HIV-positive children from Tamil Nadu for the same time period. While the sex distribution was similar, the new HIV-positive children were significantly younger than those receiving ART. Of newly positive children, 42.6% were under five compared to 18.3% of those on ART (p < 0.001). The mean (SD) age of patients who received ART was 7.6 (SD ¼ 3.2) years that was similar to the mean age of ART-screened children. However, children who received ART were significantly older as compared to new HIV-positive children [5.6 (SD ¼ 3.3) years] at the GHTM (P < 0.001). Similarly, the percentage of non-literate in the new HIV-positive children (4.2%) was significantly lower as compared to children receiving ART (11.4%).
The distribution of baseline and follow-up characteristics of children receiving ART is presented in Table 2 . At baseline, nearly 75% of the children had CD4 percent T-cell less than 20%. The rest 25% were recruited due to clinical staging. The median for CD4 percent T-cell at baseline was 14% (IQR ¼ 9-20%). Nearly 21.3% of the children had ALC <1800 and another 27.8% had ALC 1800-2799. The median for ALC was 2800 (IQR ¼ 1800-4000). The severe malnutrition based on the weight for age Z-score 35.3%. However, nearly one-fourth of them were Of the ART children, 214 (72.5%) received d4T þ 3TC þ NVP, 37 (12.5%) were on AZT þ 3TC þ NVP, 42 (14.3%) were on d4T þ 3TC þ EFV and 2 (0.7%) were on AZT þ 3TC þ EFV regimen.
Other measures of treatment response CD4 percent T-cell response. In ART children, the median increase in CD4 percent T-cell at 6 month was 10% (IQR ¼ 5-15% Table 3 ). This 6-month CD4 percent T-cell value was greater than baseline for 84.1% of the children. The median increase in CD4 percent T-cell at 12 month was 10% (IQR ¼ 4.3-14%). The CD4 percent T-cell at 12 months was greater than the baseline value in 84.3% of the children. The median (IQR) increase in CD4 percent T-cell at 18 months was 12% (6.3-17%). The CD4 percent T-cell at 18 months was greater than the baseline value in 98.2% of the children. The median increase in CD4 percent T-cell at 24 months was 15% (IQR ¼ 8-19.5%). The CD4 T-cell count at 24 months was greater than the baseline value in 95.2% of the patients.
Absolute cell count response. In ART children, the median increase in ALC at 6 months was 600 cells (IQR ¼ À200 to 1400). The ALC at 6 months was greater than the baseline value in 64.4% of the children. The median increase in ALC at 12 months was 800 (IQR ¼ À100 to 1550). The ALC at 12 months was greater than the baseline value in 73.2% of the children. The median increase in ALC at 24 months was 1050 (IQR ¼ 75-1875). The ALC at 24 months was greater than the baseline value in 78.6% of the children.
Hemoglobin response. In ART children, the median increase in HB at 6 months was 1.6 g/dl (IQR ¼ 0.4-3.0). The HB at 6 months was greater than the baseline value in 84.7% of the children. The median increase in HB at 12 months was 2.0 g/dl (IQR ¼ 0.9-3.2). The HB at 12 months was greater than the baseline value in 86.6% of the children. The median increase in HB at 24 months was 2.5 g/dl (IQR ¼ 1.5-4.1). The HB at 24 months was greater than the baseline value in 92.9% of the children.
Weight gain
In ART children, the median (IQR) increase in weight at 6 months was 2 kg (1-3). The weight at 6 months was greater than the baseline value in 77.5% of the children. The median (IQR) increase in weight at 12 months was 3 kg (2-5). The weight at 12 months was greater than the baseline value in 93.2% of the children. The median increase in weight at 24 months was 5.5 kg (IQR ¼ 5-7). The weight at 24 months was greater than the baseline value in 100% of the patients.
Tuberculosis
Of the 295 ART children, 175 (59.3%) had anti TB treatment (ATT) prior to ART. The mortality rate was 5.7% for the children who had previous ATT, which was significantly lower as compared to mortality rate (11.7%) of children who did not have ATT (p ¼ 0.08). Of the ART children, seven children developed TB post ART and the median and mean (SD) duration for development of TB after commencing ART were 5.0, 7.5 (7.1) months, respectively. These seven children received d4T þ 3TC þ NVP regimen at the baseline. Pulmonary tuberculosis and lymphnodal tuberculosis were the manifestations encountered in them.
Survival
Of the total children recruited, 24 (8.1%) died over two and half years, 1(0.3%) discharged against medical advises 6 (2%) lost for follow up and 4 (1.3%) stopped taking treatment. Of these, 260 (88.1%) children were alive. This analysis focused on two and half years follow-up period. The mean and median follow up was 11 and 10 months, respectively. The cumulative probability survival curves over two and half years follow up by sex, CD4 percent T-cell at baseline, baseline HB and weight for age interaction and absolute change in HB and weight for age interaction at follow up are presented in Figs 1-4 . The observed overall cumulative probability of survival at 6, 12, 18, 24 and 30 months was 93, 90, 89.7, 89.7 and 89.7%, respectively. Of the children died, about 50% died within the first month. However, none died after 12 months through the follow-up period. The rate of mortality was similar in both the sex (Fig. 1) . The children who had a baseline CD4 percent T-cell less than or equal to 14% had significantly (p < 0.05) higher mortality as compared to other patients (Fig. 2) . Interaction between hemoglobin and weight for age The children receiving ART who were severely malnourished and had HB less than 9 g/dl at the baseline had significantly higher mortality as compared to patients who were moderately malnourished or normal and whose HB was greater than or equal to 9 g/dl (p < 0.001). The patients who had HB less than 9 g/dl and who were moderately malnourished or normal at baseline had significantly higher mortality overtime as compared to patients who had HB greater than or equal to 9 g/dl and who were moderately malnourished or normal (p < 0.001) (Fig. 3) . Similarly, the children who were severely malnourished but had HB !9 g/dl at baseline had significantly higher mortality as compared to children who were moderately malnourished or normal and whose HB was !9 g/dl (P < 0.01). During the follow up, patients who had negative or no change in HB and in weight for age over time had significantly higher mortality as compared to patients who had positive change on both variables (P < 0.001). Similarly, the patients who had negative change in HB but had positive change in weight had significantly higher mortality over time as compared to patients who had positive change on both variables (P < 0.001) (Fig. 4) . In Cox PH model, the children who were severely malnourished at baseline, had 6.7 (0.9-49.4) times significantly higher HR for mortality as compared to children who were normal (p ¼ 0.06). The children whose ALC count was <1800 at baseline, had significantly higher mortality as compared to children whose ALC count was >4000 (p ¼ 0.05). Similarly, in the follow-up variables, the patients who have had negative change in ALC had 9.3 (1.8-46.2) times significantly higher HR for mortality as compared to patients who had positive change in 1.1-43.5 ) times significantly higher HR for mortality as compared to children who had positive change (p < 0.05). The children who had negative or no change in weight for age and HB had 18.9 (3.7-95.7) times significantly higher HR for mortality as compared to children who had positive change in both variables (p < 0.001).
Validity of change in ALC and HB in monitoring outcome The sensitivity and specificity of negative or no change in ALC in predicting the outcome (death) was 80 and 73%, respectively. The children who had negative or no change in ALC were three times more likely to be in the death group as compared to alive group [likelihood ratio (LR)þ ¼ 2.9). Similarly, the sensitivity and specificity of negative or no change in HB in predicting the outcome (death) was 65 and 85%, respectively. The children who had negative or no change in HB were nearly four times more likely to be in the death group as compared to alive group (LR þ ¼ 4.3). Phillips et al. [12] reported that the randomized controlled trials lack generalizability and may provide limited view about the population at large, while prospective cohorts allow the therapeutic effect to be assessed under usual clinical conditions. The benefits of triple drug combination therapy including protease inhibitors in children and adolescents with HIV include a decreased risk of death, improved growth [13] better immune function [14, 15] . Therefore, this study is an ideal model to evaluate the effectiveness of the ART program in the country.
Our study has shown that the survival rates are as high as other reported cohort studies [10, 11, 13] . As reported by Reddi et al. [8] , CD4 and HB at baseline were not significantly associated with mortality in the multivariate Cox PH model ( Table 4 ). Also that our mortality rate (8%) was similar to 8.6% of their study. Though the power was a concern in both studies, our study had shown that the interaction between change in Weight for age Z-score and HB during follow up was significant. In our study, only 5.8% of the children had adherence less than 95%. The severely malnourished children had significantly higher risk for mortality both in the Kaplan-Meier survival analysis, and also in the Cox PH model for baseline variables. This implied that severe malnutrition at baseline is an important risk factor. Similarly, the children who had a negative change in ALC or had not gained ALC over time, had higher HR for mortality as compared to children who had positive change in ALC over time. The children who had a negative or no change in HB during the follow up had significantly higher risk for mortality. These findings suggested that the simple and inexpensive measures such as ALC or HB could be used to monitor the progression of disease. As we did not have CD4 measurements every month, the utility of this variable for monitoring is limited. Therefore, we did not include CD4 values in the follow-up model. Thus, it may imply that that ALC would be a proxy for CD4% for children during the follow up, as this predicted the outcome well (sensitivity ¼ 80%, specificity ¼ 73% and LR þ ¼3).
In our study, nearly 50% of the deaths occurred in the first month after starting the ART, which implied that the program should intensively monitor children using simple indicators such as weight and HB though they are asymptomatic, while they seek for care for HIV infection as early as possible. Though this study has identified severe malnutrition at baseline and a negative change or non-change in ALC and weight for age and HB during follow up are important risk factors for survival in Indian children who are on ART, this finding needs to be validated from other sites data and we too need to use this indicator as monitoring tool in the program and validate it prospectively. Predictive values were not calculated as the mortality rate was only 8% and also that they are prevalent dependent statistics. However, likelihood ratio for the positive test (negative or no change) was calculated, as this is prevalence dependent statistics.
The limitation of our study is that we do not have waiting time of the children, since infection to receive the therapy that would influence the survival. Further, we do not have information on whether the mothers of these children had any antiretroviral prophylaxis during pregnancy. The finding from the Italian registry for HIV-infected children has shown a more rapid disease progression in a selected group of children whose mothers received Zidovudine prophylaxis during pregnancy as compared to agematched children of untreated mothers [16] . Despite the biological characteristics of perinatal HIV infection and difficulties in treating infants and children, our study shows the effectiveness of triple combination therapies at a population level in infants and children. As suggested by McConnel [10] , the children and adolescents who are on ARV therapy go through hormonal changes and growth spurts associated with puberty, the late complications and toxicities of exposure to ART also need to be monitored and evaluated. In summary, the program would proactively identify children with low weight for their age and have low HB very early.
